Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial

被引:126
作者
Nojomi, Marzieh [1 ]
Yassin, Zeynab [2 ]
Keyvani, Hossein [3 ]
Makiani, Mahin Jamshidi [4 ]
Roham, Maryam [4 ]
Laali, Azadeh [5 ]
Dehghan, Nasir [6 ]
Navaei, Mehrnaz [7 ]
Ranjbar, Mitra [7 ]
机构
[1] Iran Univ Med Sci, Dept Community & Family Med, Prevent Med & Publ Hlth Res Ctr, Psychosocial Hlth Res Inst,Sch Med, Tehran, Iran
[2] Iran Univ Med Sci, Hazrate Rasool Gen Hosp, Antimicrobial Resistance Res Ctr, Dept Infect Dis,Sch Med, Tehran, Iran
[3] Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Sch Med, Dept Virol, Tehran, Iran
[4] Iran Univ Med Sci, Antimicrobial Resistance Res Ctr, Tehran, Iran
[5] Iran Univ Med Sci, Firoozgar Gen Hosp, Sch Med, Dept Infect Dis, Tehran, Iran
[6] Iran Univ Med Sci, Sch Med, Dept Community & Family Med, Tehran, Iran
[7] Iran Univ Med Sci, Sch Med, Dept Infect Dis, Tehran, Iran
关键词
Arbidol; Corona virus; COVID-19; Efficacy;
D O I
10.1186/s12879-020-05698-w
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundTreatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease.MethodsUsing an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05.ResultsThe mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6days; P=0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) (P=0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19.ConclusionOur findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design.Trial registrationIRCT20180725040596N2 on 18 April 2020.
引用
收藏
页数:10
相关论文
共 26 条
[1]   Remdesivir as a possible therapeutic option for the COVID-19 [J].
Al-Tawfiq, Jaffar A. ;
Al-Homoud, Ali H. ;
Memish, Ziad A. .
TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2020, 34
[2]   COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics [J].
Amawi, Haneen ;
Abu Deiab, Ghina'a I. ;
Aljabali, Alaa A. A. ;
Dua, Kamal ;
Tambuwala, Murtaza M. .
THERAPEUTIC DELIVERY, 2020, 11 (04) :245-268
[3]  
[Anonymous], 2020, GUANGZI SHIFAN DAXUE, DOI DOI 10.16088/j.issn.1001-6600.2020.02.002
[4]   Arbidol as a broad-spectrum antiviral: An update [J].
Blaising, Julie ;
Polyak, Stephen J. ;
Pecheur, Eve-Isabelle .
ANTIVIRAL RESEARCH, 2014, 107 :84-94
[5]   Arbidol:: A broad-spectrum antiviral compound that blocks viral fusion [J].
Boriskin, Y. S. ;
Leneva, I. A. ;
Pecheur, E. -I. ;
Polyak, S. J. .
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (10) :997-1005
[6]   The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro [J].
Caly, Leon ;
Druce, Julian D. ;
Catton, Mike G. ;
Jans, David A. ;
Wagstaff, Kylie M. .
ANTIVIRAL RESEARCH, 2020, 178
[7]  
Campbell MJ, 2007, MED STAT TXB HLTH SC, P267
[8]   Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study [J].
Deng, Lisi ;
Li, Chunna ;
Zeng, Qi ;
Liu, Xi ;
Li, Xinghua ;
Zhang, Haitang ;
Hong, Zhongsi ;
Xia, Jinyu .
JOURNAL OF INFECTION, 2020, 81 (01) :E1-E5
[9]   The Antiviral Drug Arbidol Inhibits Zika Virus [J].
Fink, Susan L. ;
Vojtech, Lucia ;
Wagoner, Jessica ;
Slivinski, Natalie S. J. ;
Jackson, Konner J. ;
Wang, Ruofan ;
Khadka, Sudip ;
Luthra, Priya ;
Basler, Christopher F. ;
Polyak, Stephen J. .
SCIENTIFIC REPORTS, 2018, 8
[10]   Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [J].
Gao, Jianjun ;
Tian, Zhenxue ;
Yang, Xu .
BIOSCIENCE TRENDS, 2020, 14 (01) :72-73